General Virology encompasses the study of viruses, microscopic infectious agents that can cause a wide range of diseases in humans, animals, plants, and even bacteria. Some viruses also have an outer envelope derived from the host cell membrane. Virologists study various aspects of viruses, including their structure, replication, transmission, pathogenesis, and evolution. Understanding these fundamental aspects of virology is crucial for the development of vaccines to prevent viral infections.
Vaccines work by stimulating the body's immune system to recognize and respond to specific viral antigens, such as viral proteins or surface molecules. By mimicking natural infection without causing illness, vaccines prime the immune system to produce antibodies and memory cells that provide long-lasting protection against future encounters with the virus. There are several types of vaccines, including live attenuated vaccines, inactivated vaccines, subunit vaccines, recombinant vaccines, and nucleic acid vaccines. Each type of vaccine utilizes different strategies to present viral antigens to the immune system and induce a protective immune response.
Live attenuated vaccines contain weakened forms of the virus that can still replicate but cause minimal or no disease. Inactivated vaccines contain viruses that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are safe but may require booster doses to maintain immunity. Subunit vaccines contain purified viral antigens or protein subunits that stimulate an immune response. These vaccines are highly purified and do not contain live virus, making them safe for use in individuals with weakened immune systems. Recombinant vaccines are produced by genetically engineering viruses to express specific antigens. These vaccines are highly specific and can be tailored to target specific viral proteins or surface molecules. Examples include the recombinant hepatitis B vaccine and the recombinant subunit vaccine against COVID-19.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe